Table 2 Study drug up- and down-titration

(A) Baseline treatment algorithm

Investigational group

Control group

Mean HCO₃ ^- of two measurements

<18 mmol/L

5,040 mg (2 capsules TID)

2,520 mg (1 capsule TID)

18 to 19 mmol/L

4,200 mg (2 capsules BID, 1 capsule QD)

1,680 mg (1 capsule BID)

19.1 to 20.0 mmol/L

2,520 mg (1 capsule TID)

Monitor

>20 mmol/L

1,680 mg (1 capsule BID)

(B) Follow-up visit treatment algorithm

Investigational group and control group

Difference to target HCO₃ ^- level

−1 mmol/L

Add 1,680 mg to the previous daily dosage (+1 capsule BID)

−2 mmol/L

Add 3,360 mg to the previous daily dosage (+2 capsules BID)

≤ −3 mmol/L

Add 5,040 mg to the previous daily dosage (+2 capsules TID)

+1 mmol/L

Subduct 1,680 mg from the previous daily dosage (−2 capsules)

+2 mmol/L

Subduct 3,360 mg from the previous daily dosage (−4 capsules)

≥ +3 mmol/L

Subduct 5,040 mg from the previous daily dosage (−6 capsules)